The GLP-1 Opportunity Everyone Is Missing

The Pattern We Keep Repeating

Weekly injections. Rapid weight loss. Quieted cravings. Another pharmaceutical promise for modern bodies struggling with ancient biology.

GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro are being celebrated as the dawn of a new era in obesity treatment. Celebrities are raving. Wall Street is cheering. Millions are lining up.

Before we crown this class of drugs as the answer to our metabolic crisis, we need to take an honest look at our history, our biology, and our remarkable talent for collective blindness. Including, in this case, the very literal blindness these drugs may cause.

This is not the first time we have celebrated a pharmaceutical breakthrough in the battle against body fat.

And it will not be the last time we pay for it.

A Shot at Simplicity

The appeal is obvious. GLP-1 medications mimic a natural hormone that tells your body it is full. The result is reduced appetite and increased satiety, which is especially helpful for people consuming nutrient-poor foods that trigger hunger, addiction, and cravings.

One injection turns down the food noise. It curbs emotional eating. It delivers fast, noticeable results on the scale.

But excitement is not insight. And fast is not free.

We Have Been Here Before

As I wrote in WildFit, the weight loss industry has a long and devastating history of miracle drugs that made incredible promises and caused terrible outcomes.

Fen-Phen arrived in the 1990s. Dramatic weight loss. Then it started destroying heart valves. The FDA pulled it in 1997, but not before irreversible damage and billions in profits had accumulated.

Sibutramine came next, promising appetite suppression. It increased heart attack and stroke risk. Gone by 2010.

Orlistat tried a different approach by blocking fat absorption. In practice, it delivered greasy stools, digestive distress, and regret. Still technically approved. Rarely used.

Lorcaserin launched in 2012 with new precision. Less than a decade later, pulled for cancer risk.

Each one arrived as a solution. Each one ended as a cautionary tale.

You would think we would learn.

But This Time Is Different, Right?

Today's rising stars, semaglutide and tirzepatide, are backed by stronger science and smarter marketing. The results for many people are genuinely dramatic. Significant weight loss. Reduced A1C. Lower hunger.

So what is the problem?

Three things.

The Side Effects Are Not Minor

Nausea. Vomiting. Diarrhea. Gallbladder issues. Emotional shifts. Open questions about long-term effects on the pancreas and thyroid.

And now something far more serious: NAION, or non-arteritic anterior ischemic optic neuropathy. A rare but irreversible form of vision loss.

In Denmark, NAION cases more than doubled after semaglutide's release. The European Medicines Agency has issued warnings. A July 2024 study in JAMA Ophthalmology analyzed data from over 16,800 patients and found that semaglutide users with type 2 diabetes had 4.28 times greater risk of NAION. Users taking it purely for weight loss faced seven times the risk.

As of mid-2025, nearly 2,000 lawsuits have been consolidated in U.S. federal court against Novo Nordisk and Eli Lilly. The fastest-growing category is NAION-related blindness. Over 1,800 plaintiffs are seeking settlements between $200,000 and $1,000,000 each. That is potentially over $1.8 billion in liabilities.

The companies' stock prices have barely flinched.

You Lose the Wrong Weight

These drugs suppress appetite so aggressively that users often eat too little protein. The result is that weight loss includes substantial lean muscle mass, the very tissue that supports metabolism and long-term weight control.

When people stop the drug, they regain the weight. But it comes back as fat, not muscle. They become heavier, weaker, and more metabolically fragile than when they started.

This is not a minor footnote. It is the central flaw in the entire approach.

Appetite Suppression Is Not Nutritional Healing

Most modern eaters are already overfed and undernourished. That is a hallmark of evolutionary mismatch. We are eating constantly, but we are eating the wrong things.

GLP-1 drugs suppress quantity, not quality. Users often reduce their intake of nutrient-dense foods like protein and vegetables because those foods are less emotionally rewarding when appetite is chemically flattened.

So when the drug stops, old habits return. Appetite returns. The weight returns. Usually with interest.

If you have not healed the relationship with food, biologically, psychologically, and emotionally, the drug is just a pause button. And when you unpause, the music starts again. Usually louder.

As I explore in The Gap book, this is what happens when we try to use modern interventions to override millions of years of biological programming without understanding why that programming exists in the first place.

The Real Opportunity

Here is the part almost everyone is missing.

Your body already knows how to do what GLP-1 drugs are trying to do. You produce GLP-1 naturally. The question is whether you are creating the conditions for that production or suppressing it with the way you eat.

This is exactly what the WILDFIT program has been teaching for over a decade. Not calorie restriction. Not willpower. Not pharmaceutical intervention. Instead, alignment with human biology.

When you eat nutrient-dense foods like meat, fish, eggs, and poultry, when you stop flooding your system with the carbohydrate-rich foods that trigger cravings and storage, when you eat in patterns that stabilize blood sugar and trigger natural satiety, your body does what it was designed to do.

Internal hormone balance. Natural appetite control. Natural blood sugar regulation. Natural release of weight.

No needles. No nausea. No blindness. No lawsuits.

The Wake-Up Call

GLP-1 drugs are the latest chapter in a long story of promises and pitfalls. The real risk is not just the side effects. It is the illusion that these drugs solve the underlying problem.

They do not. They suppress the symptom.

The real opportunity is to use this moment as a wake-up call. Instead of mimicking your own hormones with drugs, why not create the conditions for your hormones to work properly on their own?

Sustainable health & wellness has never come from a needle. It comes from understanding what your body actually needs and then giving it exactly that.

Let us not repeat the history of Fen-Phen, Meridia, and Belviq.

Let us address the real issue. Not just how much we eat, but what we eat, why we eat it, and who we are when we do.

That is the only weight loss solution that has ever worked in the long run.